Lung cancer targeted drug and chemotherapy drug genomes and application thereof in lung cancer clinical drug treatment

A genome and lung cancer technology, applied in the direction of drug combination, antineoplastic drugs, pharmaceutical formulations, etc., to improve the effect and reduce the effect of side effects

Inactive Publication Date: 2020-12-25
合肥金域医学检验实验室有限公司
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Malignant tumors are currently a type of disease that most needs individualized drug treatment. However, in cancer chemotherapy, there are large individual differences in both efficacy and side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lung cancer targeted drug and chemotherapy drug genomes and application thereof in lung cancer clinical drug treatment
  • Lung cancer targeted drug and chemotherapy drug genomes and application thereof in lung cancer clinical drug treatment
  • Lung cancer targeted drug and chemotherapy drug genomes and application thereof in lung cancer clinical drug treatment

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] A lung cancer targeted drug and chemotherapy drug genome:

[0034] The genome and variation types of the lung cancer targeted drugs are shown in Table 1:

[0035] Table 1

[0036]

[0037] The genome and variation types of the chemotherapy drugs for lung cancer are shown in Table 2:

[0038] Table 2

[0039]

[0040]

[0041] The mutation sites of the genome of the lung cancer targeted drug are shown in Table 3:

[0042] table 3:

[0043]

[0044]

[0045]

[0046]

[0047] The mechanism of the canceration of the genome of the lung cancer targeted drug is shown in Table 4:

[0048] Table 4

[0049]

[0050]

[0051]

[0052]

[0053]

[0054]

[0055]

[0056]

Embodiment 2

[0058] Five male patients with non-small cell lung cancer aged between 65 and 70 were selected. Under the guidance of clinicians, 5 patients were treated with gemcitabine, pemetrexed, docetaxel + paclitaxel, cisplatin + card Platinum + nedaplatin and vinorelbine were used for medication, and the medication cycle was 3 months. Fresh ascites and ascites were collected, cells were obtained by centrifugation, and genomic DNA was extracted, and the integrity of DNA fragments was evaluated by agarose gel electrophoresis. Comprehensively evaluate the quality of the samples submitted for inspection based on the proportion of tumors, the total amount of DNA, and integrity, and perform multiple PCR amplification to construct a sequencing library, and then perform NGS sequencing detection, and then combine bioinformatics analysis to determine the existence of mutant genes. Combined with the sequencing parameters to comprehensively evaluate the quality of the sequencing, the evaluation res...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses lung cancer targeted drug and chemotherapy drug genomes and an application thereof in lung cancer clinical drug treatment. The targeted drug genome comprises AKT1, ALK, BRAF, CCND1, CDKN2A, DDR2, EGFR, ERBB2, ERBB4, FBXW7, FGFR1, FGFR2, FGFR3, HRAS, IGF1R, KDR, KIT, KRAS, MAP2K1, MET, NF1, NRAS, NTRK1, NTRK3, PDGFRA, PIK3CA, PTEN, RET, ROS1, STK11 and TP53; and the chemotherapy drug genome comprises ABCB1, CDA, CEP72, CYP1B1, CYP2C8, DPYD, ERCC1, ERCC2, GSTM, GSTP1, MTHFR, RRM1, SLCO1B1, TEKT4, TPMT, TYMS, UMPS, XPC and XRCC1. The lung cancer targeted drug and chemotherapy drug genomes disclosed by the invention are applied to guidance of clinical precise chemotherapy of the lung cancer or auxiliary diagnosis of the lung cancer and curative effect and after-healingmonitoring, can provide the most effective drug selection for lung cancer patients with drug resistance or toxic and side effect intolerance caused by conventional drugs and targeted and chemotherapydrug requirements, improve the drug treatment effect, and reduce the toxic and side effects of the drugs.

Description

technical field [0001] The invention belongs to the field of pharmacogenomics, and in particular relates to a lung cancer targeting drug and chemotherapy drug genome and its application in clinical drug treatment of lung cancer. Background technique [0002] Studies have shown that tumor is a complex disease caused by changes in single or multiple genes that lead to related gene dysfunction. Therefore, gene changes are also the most fundamental reason for the occurrence and development of tumors. Due to the individual differences in gene mutations, there are obvious individual differences in the responses of different tumor patients to various drugs. This difference in curative effect is obviously related to the differential expression and polymorphism of individual tumor-related genes in patients. Therefore, the mutation status of tumor-related genes plays a very important role in the process of individualized treatment such as tumor diagnosis, treatment, and prognosis. As...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P35/00
CPCA61K45/00A61P35/00
Inventor 李晓华李志强陈浩
Owner 合肥金域医学检验实验室有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap